HK Stock Market Move | ALPHAMAB-B(09966) surged over 8% as the first patient received treatment in the Phase I/II clinical trial JSKN033.

ALPHAMAB-B (09966) rose by more than 8%, at the time of writing, it had risen by 8.67% to HK$3.51 with a turnover of HK$5.8347 million. On the news front, Kangning Jerry Biopharmaceutical announced this morning that the high-concentration subcutaneous injection compound formulation JSKN033, a HER2 bispecific antibody-drug conjugate (ADC) combined with a PD-L1 inhibitor, completed the first patient dosing in the Phase I/II clinical study (Study number: JSKN033-102) for the treatment of advanced metastatic solid tumors at Fudan University Affiliated Cancer Hospital. JSKN033 is the world's first ADC and PD-L1 inhibitor high-concentration compound formulation to enter human studies via subcutaneous injection developed independently by Kangning Jerry. By combining immunotherapy (KN035) with the ADC (JSKN003) to enhance efficacy, and by optimizing the administration pathway, both safety and convenience have been improved. In the first Phase I/II clinical study conducted in Australia, JSKN033 demonstrated good safety and promising anti-tumor activity.